New stock news | Annoyance Udah Hong Kong Stock IPO prospectus invalid

Annor() (referred to as Annor) submitted its Hong Kong IPO prospectus on September 30, 2025, which became invalid on March 30, 2026, after six months. At the time of submission, Bank of China International and GUOTAI JUNAN I are its joint sponsors. The prospectus shows that Annor is a company focused on molecular diagnostics-based IVD medical devices and omics life science research services, specializing in NGS-based prenatal testing IVD products. The company's clinical sequencing solutions include self-produced gene sequencing-based IVD test kits, gene sequencers, and bioinformatics analysis software, as well as supporting technical services and laboratory design services. The company's customers mainly include hospitals with prenatal diagnostic certifications and Independent Clinical Laboratories (ICL). These institutional customers purchase the company's IVD products, and the company charges fees based on the number and type of IVD products purchased by these customers.